Inspire Medical Systems (INSP) Stock Looks Fully Priced On Cash Flow

Inspire Medical Systems has seen its share price fall sharply in recent years, and the key issue now is whether the current market value still reflects what its cash flows can reasonably support. With investors digesting weaker recent returns alongside changing expectations for the business, the stock has become a live test of what its cash generation is really worth.

• The share price has declined 75.7% over 5 years, which puts pressure on the case that future cash flows can justify even today's reduced valuation.
• Recent coding improvements for its sleep apnea therapy may support clearer reimbursement and more predictable revenue, which can be important for assessing Inspire Medical Systems' long term cash flows.
• What if you looked at Inspire Medical Systems through its earnings instead? See why Inspire Medical Systems's 19.1x P/E tells a different valuation story.

For investors, the debate is whether the cash flows implied by Inspire Medical Systems' current business outlook are enough to justify where the stock now trades.

If you are weighing Inspire Medical Systems against other potential opportunities focused on cash generation, it can help to compare it with companies filtered through 42 high quality undervalued stocks.

Does Inspire Medical Systems Look Pricey on Cash Flow?

The Discounted Cash Flow (DCF) model values Inspire Medical Systems by estimating all the cash it can generate for shareholders and then discounting that back to today. On the latest figures, the business produced trailing twelve month free cash flow of about $95.8 million, and the DCF framework assumes this moves into a period of softer cash generation before settling into relatively flat long run projections rather than aggressive expansion.

Those cooling cash flow assumptions lead the model to an intrinsic value that sits meaningfully below the current share price of $66.53. The recent Q3 2026 loss and softer sales tied to coding and billing issues help explain why the DCF outcome is cautious, even though new CPT codes from 2028 are expected to bring more clarity on reimbursement. To see how this valuation compares with other stocks assessed on the same cash flow basis, you can review the detailed output for Inspire Medical Systems alongside similar businesses. Find out what Inspire Medical Systems could be worth using our Discounted Cash Flow (DCF) estimate.

The Inspire Medical Systems Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Inspire Medical Systems valuation puzzle leaves off by spelling out which future growth, margin and earnings paths would need to play out for the share price to sit meaningfully above or below today's level, and they live on Simply Wall St's Community page. Each narrative treats Inspire Medical Systems' fair value as a thesis that can be tracked over time, rather than a single moment-in-time number, so you can watch how the reasoning holds up as new information arrives.

On Inspire Medical Systems, the community split is between investors who see enough reimbursement clarity to keep the story intact and those who think legal and coding risks now dominate the equation.

Bull case: roughly fairly valued

"Normalization of coding and reimbursement for Inspire Medical Systems, including clearer pathways across payers in 2026 and the AMA approval of new Category I CPT codes..."

Discover why this Narrative puts Inspire Medical Systems at roughly fairly valued.

Bear case: 66% overvalued

"While proposed 2027 Medicare facility reimbursement levels for Inspire procedures are higher for hospitals and ambulatory surgery centers, the projected reduction in physician reimbursement and the current estimate of US$120 million to US$130 million in annual coding and reimbursement headwinds..."

Explore why this Narrative puts Inspire Medical Systems at 66% overvalued.

Inspire Medical Systems: why valuation is only half the story

Price and cash flows tell a lot about Inspire Medical Systems, yet Simply Wall St's checks have also flagged other potential concerns that thoughtful investors often weigh carefully before committing fresh capital. Take a closer look at 1 warning sign before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com